Impact of multi-disciplinary treatment strategy on systolic heart failure outcome

Table 3 Results of Cox model of recurrent events of hospitalization in HF patients

Variables	β	S.E.	HR	HR 95% CI	p
Group
non-HFDMP	ref.		1.00
HFDMP	−1.03	0.62	0.36	0.11 – 1.19	.09
Age	0.03	0.02	1.03	0.99 – 1.06	.14
Gender
Female	ref.		1.00
Male	0.23	0.29	1.26	0.71 – 2.22	.43
Ischemic CM	−0.32	0.46	0.72	0.29 – 1.78	.48
Hypertension	−0.42	0.48	0.65	0.25 – 1.68	.38
Diabetes mellitus	−0.55	0.38	0.58	0.28 – 1.21	.14
Hyperlipidemia	0.00	0.68	1.00	0.27 – 3.77	1.00
Stroke	0.78	0.56	2.18	0.72 – 6.54	.17
Old MI	0.10	0.59	1.11	0.35 – 3.51	.87
PAD	0.51	0.52	1.67	0.60 – 4.67	.33
CKD	−0.78	0.52	0.46	0.17 – 1.26	.13
Atrial Fibrillation
Without AF	ref.		1.00
Paroxysmal	−0.30	0.61	0.74	0.22 – 2.47	.63
Persistent	−2.06	1.05	0.13	0.02 – 1.01	.05
Permanent	−0.32	0.79	0.73	0.15 – 3.42	.69
PCI	0.44	0.64	1.55	0.44 – 5.39	.49
LVEF	0.01	0.03	1.01	0.96 – 1.06	.73
Medication
ACEI/ARB	0.13	0.58	1.14	0.37 – 3.54	.82
β-blocker	−1.70	0.44	0.18	0.08 – 0.43	<.01
Aldactone	0.98	0.54	2.68	0.93 – 7.68	.07
Diuretics	−0.79	0.54	0.45	0.16 – 1.29	.14
Digoxin	0.22	0.47	1.25	0.50 – 3.10	.64
ICD	0.96	0.61	2.60	0.78 – 8.63	.12
CRT	−1.15	1.37	0.32	0.02 – 4.65

Abbreviations: HFDMP heart failure disease management program, CM cardiomyopathy, HF heart failure, MI myocardial infarction, PAD peripheral artery disease, CKD chronic kidney disease, AF atrial fibrillation, PCI percutaneous coronary intervention, LVEF left ventricular ejection fraction, ACEI angiotensin converted enzyme inhibitor, ARB angiotensin receptor blocker, ICD implantable cardioverter defibrillator, CRT cardiac resynchronization therapy, HR Hazard ratio, CI confidence interval

ISSN: 1471-2261